Xencor, Inc. XNCR
34.05 USD -0.98 (-2.80%)
At closeNov 5, 2026, 4:39 PM EST
34.05 0.00 0.00%
After hours · Nov 5, 4:39 PM ET
33.96 Day range 35.81
10.38 52-week range 35.81
- YTD
- +122.40%
- 1 year
- +136.95%
News
benzinga.com Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target Cantor Fitzgerald analyst Steve Seedhouse reiterates Xencor (NASDAQ:XNCR) with a Overweight and maintains $70 price target.
zacks.com Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.
benzinga.com Xencor Q3 EPS $0.50 Beats $(0.73) Estimate, Sales $116.520M Beat $78.587M Estimate Xencor (NASDAQ:XNCR) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.73) by 168.49 percent. This is a 725 percent increase over losses of $(0.08) per…
businesswire.com Xencor Reports Third Quarter 2026 Financial Results PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Truist Securities Maintains Buy on Xencor, Raises Price Target to $40 Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.
benzinga.com RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43 RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.
benzinga.com Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44 Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.- benzinga.com Wedbush Maintains Outperform on Xencor, Raises Price Target to $45 Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $30 to $45.
seekingalpha.com Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg,…
marketbeat.com Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO…
seekingalpha.com Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).
benzinga.com Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
gurufocus.com Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod
businesswire.com Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $30 price target.
businesswire.com Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will…
defenseworld.net Xencor (NASDAQ:XNCR) Shares Up 4.6% – What’s Next? Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) were up 4.6% during mid-day trading on Monday. The company traded as high as $24.66 and last traded at $24.8920. 290,326 shares were traded…- benzinga.com Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29 Truist Securities analyst Gregory Renza reiterates Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $27 to $29.
defenseworld.net Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE Bank of America Corp DE bought a new stake in shares of Xencor, Inc. (NASDAQ: XNCR) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 360,396 shares of…
benzinga.com B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26 B of A Securities analyst Alec Stranahan maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $20 to $26.
defenseworld.net Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…- benzinga.com Barclays Maintains Overweight on Xencor, Raises Price Target to $35 Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $27 to $35.
defenseworld.net Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the…- benzinga.com JP Morgan Maintains Neutral on Xencor, Raises Price Target to $21 JP Morgan analyst Brian Cheng maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $14 to $21.
businesswire.com Xencor to Present at the 2026 Cantor Global Healthcare Conference PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Raymond James Maintains Strong Buy on Xencor, Raises Price Target to $46 Raymond James analyst Sean McCutcheon maintains Xencor (NASDAQ:XNCR) with a Strong Buy and raises the price target from $40 to $46.
defenseworld.net Xencor (NASDAQ:XNCR) Sets New 52-Week High – Should You Buy? Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares…
defenseworld.net Dimensional Fund Advisors LP Buys 45,599 Shares of Xencor, Inc. $XNCR Dimensional Fund Advisors LP boosted its holdings in Xencor, Inc. (NASDAQ: XNCR) by 3.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange…- benzinga.com RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20 RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $19 to $20.
- benzinga.com Wedbush Maintains Outperform on Xencor, Raises Price Target to $30 Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $26 to $30.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44 Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $43 to $44.
zacks.com Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.- benzinga.com Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.79) by 62.82 percent. This is a 29.27 percent increase over losses of $(0.41) per…
businesswire.com Xencor Reports Second Quarter 2026 Financial Results PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.
businesswire.com Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune…
benzinga.com AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings expectations. Other big gainers include NUAI, IREN, XNCR, HUT, CIFR, CLSK, NUVB, AXTI, ATEX, APLD, and…
zacks.com Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in…- benzinga.com Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27 Details of the Proffered Paper Oral PresentationTitle: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)Presenter: Sumanta Pal, M.D.,…
benzinga.com Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27 Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $29 to $27.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.- benzinga.com JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13 JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $18 to $13.
benzinga.com Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.- benzinga.com Barclays Maintains Overweight on Xencor, Raises Price Target to $27 Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $26 to $27.